2.30%
-31.29%
-53.73%
-29.81%
-29.05%
81.43%
21.99%
AI Spotlight on JANX
Create a Free
Company Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.Janux Therapeutics, Inc.
is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies.The company was incorporated in 2017 and is headquartered in La Jolla, California.
Market Data
| Last Price | 30.68 |
| Change Percentage | 2.30% |
| Open | 30.3 |
| Previous Close | 29.99 |
| Market Cap ( Millions) | 1813 |
| Volume | 517742 |
| Year High | 71.71 |
| Year Low | 29.63 |
| M A 50 | 43.6 |
| M A 200 | 46.19 |
Financial Ratios
| FCF Yield | -2.44% |
| Dividend Yield | 0.00% |
| ROE | -9.22% |
| Debt / Equity | 2.25% |
| Net Debt / EBIDTA | 421.11% |
| Price To Book | 1.7 |
| Price Earnings Ratio | -25.27 |
| Price To FCF | -41.05 |
| Price To sales | 171.26 |
| EV / EBITDA | -14.52 |
News
- Jan -24 - Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
- Jan -08 - Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
- Jan -03 - Best-Performing Stocks Of 2024
- Dec -04 - Why Janux Therapeutics Crushed the Market Today
- Dec -04 - JANX Stock Hits Record High on Prostate Cancer Study Data
- Dec -03 - Janux Therapeutics Announces Proposed Public Offering
- Dec -03 - Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
- Dec -03 - Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
- Dec -02 - Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
- Nov -25 - Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
- Nov -19 - Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
- Nov -06 - Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
- Sep -13 - Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?
- Aug -07 - Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
- Jul -22 - Janux Therapeutics Announces Updates to Board of Directors
- Apr -17 - Take the Money and Run: 3 Overbought Stocks to Sell ASAP
- Apr -16 - These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
- Apr -15 - Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
- Apr -12 - Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
- Apr -12 - Why Janux Therapeutics Stock Is Crushing It This Week
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Immunotherapies
Expected Growth : 11.3 %
What the company do ?
Janux Therapeutics' novel immunotherapies harness the power of bispecific antibodies to redirect immune cells to target and eliminate cancer cells, enhancing anti-tumor responses.
Why we expect these perspectives ?
Janux Therapeutics' novel immunotherapies drive 11.3% growth, fueled by increasing adoption in cancer treatment, advancements in T-cell and bispecific antibody technologies, and a growing pipeline of promising candidates. Strong partnerships, strategic collaborations, and a robust research and development focus also contribute to the company's rapid expansion.
Janux Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| T cell engagers | Janux Therapeutics' T cell engagers are bispecific antibodies designed to redirect T cells to tumor cells, enhancing the immune system's ability to fight cancer. |
| CD28-based costimulatory antibodies | Janux Therapeutics' CD28-based costimulatory antibodies are designed to enhance T cell activation and proliferation, promoting an anti-tumor immune response. |
| Tumor-targeted immunomodulators | Janux Therapeutics' tumor-targeted immunomodulators are designed to selectively modulate the tumor microenvironment, enhancing anti-tumor immunity and reducing immune suppression. |
Janux Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Janux Therapeutics, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing novel and innovative therapies.
Bargaining Power Of Customers
Janux Therapeutics, Inc. has a diverse customer base, and no single customer has significant bargaining power over the company.
Bargaining Power Of Suppliers
Janux Therapeutics, Inc. relies on a few key suppliers for raw materials and services, but the company has developed relationships with multiple suppliers to mitigate the bargaining power of any one supplier.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services, posing a significant threat to Janux Therapeutics, Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and Janux Therapeutics, Inc. faces intense rivalry from established companies and new entrants, which can lead to pricing pressure and reduced market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.65% |
| Debt Cost | 3.95% |
| Equity Weight | 93.35% |
| Equity Cost | 23.30% |
| WACC | 22.02% |
| Leverage | 7.13% |
Janux Therapeutics, Inc. : Quality Control
Janux Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| IONS | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| IOVA | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has … |
| RVMD | Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Denali Therapeutics
A-Score
1-Year Total Return ->
🥈
Amicus Therapeutics
A-Score
1-Year Total Return ->
🥉
Revolution Medicines
A-Score
1-Year Total Return ->
4
Ionis Pharmaceuticals
A-Score
1-Year Total Return ->
5
Janux Therapeutics
A-Score
1-Year Total Return ->
6
